Publications - Page 39 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP)
Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report.

Triantafyllidi H, Iordanidis D, Montani D, Samiotis E, Mademli M, Vlachos S, Mpahara A, Humbert M, Dorfmuller P, Tsagkaris I, Iliodromitis E.

Respir Med Res. 2022 Nov;82:100943.
Hypertension pulmonaire (HTP)
Molecular Function and Contribution of TBX4 in Development and Disease.

Karolak JA, Welch CL, Mosimann C, Bzdega K, West JD, Montani D, Eyries M, Mullen MP, Abman SH, Prapa M, Gräf S, Morrell NW, Hemnes AR, Perros F, Hamid R, Logan MPO, Whitsett J, Galambos C, Stankiewicz P, Chung WK, Austin ED; TBX4Life Initiative.

Am J Respir Crit Care Med. 2022 Nov 11.
Hypertension pulmonaire (HTP)
First histological description of pulmonary and vascular abnormalities of pulmonary hypertension associated with KDR pathogenic variant.

Riou M, Canuet M, Ghigna MR, Eyries M, Chenard MP, Porzio M, Olland A, Humbert M, Kessler R, Montani D.

Eur Respir J. 2022 Nov 3;60(5):2201197.
Hypertension pulmonaire (HTP)
PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.

Weatherald J, Humbert M.

Respirology. 2022 Nov 1.
Hypertension pulmonaire (HTP)
Impact of pulmonary hypertension on lung cancer management.

Durin L, Noël-Savina E, Héluain V, Mattei P, Mazières J, Prévot G.

Respir Med Res. 2022 Nov;82:100964.
Hypertension pulmonaire (HTP)
The evolving landscape of pulmonary arterial hypertension clinical trials.

Weatherald J, Boucly A, Peters A, Montani D, Prasad K, Psotka MA, Zannad F, Gomberg-Maitland M, McLaughlin V, Simonneau G, Humbert M; Evolving Landscape of Pulmonary Arterial Hypertension and Redesigning Pulmonary Arterial Hypertension Clinical Trials Task Force of the 18th Global CardioVascular Clinical Trialists Forum.

Lancet. 2022 Nov 26;400(10366):1884-1898.
Hypertension pulmonaire (HTP)
The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload

Mulvaney EP, Renzo F, Adão R, Dupre E, Bialesova L, Salvatore V, Reid HM, Conceição G, Grynblat J, Llucià-Valldeperas A, Michel JB, Brás-Silva C, Laurent CE, Howard LS, Montani D, Humbert M, Vonk Noordegraaf A, Perros F, Mendes-Ferreira P, Kinsella BT.

Front Cardiovasc Med. 2022 Dec 14;9:1063967.
Hypertension pulmonaire (HTP)
Lipidomic Profile Analysis of Lung Tissues Revealed Lipointoxication in Pulmonary Veno-Occlusive Disease.

Khoury S, Beauvais A, Colas J, Saint-Martin Willer A, Perros F, Humbert M, Vandebrouck C, Montani D, Ferreira T, Antigny F.

Biomolecules. 2022 Dec 14;12(12):1878.
Hypertension pulmonaire (HTP)
Molecular Function and Contribution of TBX4 in Development and Disease.

Karolak JA, Welch CL, Mosimann C, Bzdega K, West JD, Montani D, Eyries M, Mullen MP, Abman SH, Prapa M, Gräf S, Morrell NW, Hemnes AR, Perros F, Hamid R, Logan MPO, Whitsett J, Galambos C, Stankiewicz P, Chung WK, Austin ED; TBX4Life Initiative.

Am J Respir Crit Care Med. 2022 Nov 11.
Hypertension pulmonaire (HTP)
Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies.

Fauché A, Presles E, Sanchez O, Jaïs X, Le Mao R, Robin P, Pernod G, Bertoletti L, Jego P, Parent F, Lemarié CA, Leven F, Le Roux PY, Salaun PY, Nonent M, Girard P, Lacut K, Savale L, Mélac S, Guégan M, Mismetti P, Laporte S, Leroyer C, Montani D, Couturaud F, Tromeur C; PADIS-PE Investigators.

J Thromb Haemost. 2022 Dec;20(12):2850-2861.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report.

Molecular Function and Contribution of TBX4 in Development and Disease.

First histological description of pulmonary and vascular abnormalities of pulmonary hypertension associated with KDR pathogenic variant.

PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.

Impact of pulmonary hypertension on lung cancer management.

The evolving landscape of pulmonary arterial hypertension clinical trials.

The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload

Lipidomic Profile Analysis of Lung Tissues Revealed Lipointoxication in Pulmonary Veno-Occlusive Disease.

Molecular Function and Contribution of TBX4 in Development and Disease.

Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies.